ADAPTIMMUNE THERAPEUTICS PLC Net Cash Provided by (Used in) Operating Activities, Continuing Operations
ADAPTIMMUNE THERAPEUTICS PLC (ADAPY) reported Net Cash Provided by (Used in) Operating Activities, Continuing Operations of $73.20 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-24.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations · last filed 2025-03-24
- ADAPTIMMUNE THERAPEUTICS PLC net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-03-31 was -$28.44M.
- ADAPTIMMUNE THERAPEUTICS PLC net cash provided by (used in) operating activities, continuing operations for the quarter ending 2016-12-31 was $2.37M.
- ADAPTIMMUNE THERAPEUTICS PLC net cash provided by (used in) operating activities, continuing operations for the quarter ending 2016-09-30 was -$15.37M.
- ADAPTIMMUNE THERAPEUTICS PLC net cash provided by (used in) operating activities, continuing operations for the quarter ending 2016-06-30 was -$16.49M.
- ADAPTIMMUNE THERAPEUTICS PLC net cash provided by (used in) operating activities, continuing operations for fiscal 2024 was $73.20M.
- ADAPTIMMUNE THERAPEUTICS PLC net cash provided by (used in) operating activities, continuing operations for fiscal 2016 was -$48.17M.
- ADAPTIMMUNE THERAPEUTICS PLC net cash provided by (used in) operating activities, continuing operations for fiscal 2015 was -$29.67M, a 180.54% decline from fiscal 2014.
- ADAPTIMMUNE THERAPEUTICS PLC net cash provided by (used in) operating activities, continuing operations for fiscal 2014 was $36.84M.
| Period end | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2024-12-31 | $73.20M 10-K · filed 2025-03-24 | |||
| 2017-03-31 | -$28.44M 10-Q · filed 2017-05-10 | -$26.07M derived: sum of 2 quarters · filed 2017-05-10 | -$41.44M derived: sum of 3 quarters · filed 2017-05-10 | -$57.93M derived: sum of 4 quarters · filed 2017-05-10 |
| 2016-12-31 | $2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | -$13.00M derived: sum of 2 quarters · filed 2017-03-13 | -$29.49M derived: sum of 3 quarters · filed 2017-03-13 | -$48.17M 10-K · filed 2017-03-13 |
| 2016-09-30 | -$15.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$31.86M derived: sum of 2 quarters · filed 2016-11-10 | -$50.54M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | -$16.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | -$35.17M 10-Q · filed 2016-08-08 | ||
| 2016-03-31 | -$18.68M 10-Q · filed 2017-05-10 | |||
| 2015-12-31 | -$18.06M 10-K · filed 2017-03-13 | |||
| 2015-09-30 | -$276.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$8.18M derived: sum of 2 quarters · filed 2016-11-10 | -$13.82M 10-Q · filed 2016-11-10 | |
| 2015-06-30 | -$7.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | -$13.54M 10-Q · filed 2016-08-08 | -$29.67M 10-K · filed 2017-03-13 | |
| 2015-03-31 | -$5.64M 10-Q · filed 2016-05-12 | |||
| 2014-06-30 | $36.84M 10-K · filed 2017-03-13 | |||
| 2013-06-30 | -$10.67M 8-K · filed 2016-07-08 |